Head and Neck Cancers

Latest News

FDA Grants Traditional Approval to Selpercatinib for Advanced/Metastatic RET Fusion-Positive Thyroid Cancer
FDA Grants Traditional Approval to Selpercatinib for Advanced/Metastatic RET Fusion-Positive Thyroid Cancer

June 12th 2024

This traditional approval updates the accelerated approval that selpercatinib received in 2020 for this indication in patients 12 years and older.

Identifying and Managing Oral Adverse Effects From Cancer Treatments
Identifying and Managing Oral Adverse Effects From Cancer Treatments

June 5th 2024

HPV Vaccinations Lowered HPV-Caused Cancers Rates in Patients Under the Age of 40
HPV Vaccinations Lowered HPV-Caused Cancers Rates in Patients Under the Age of 40

May 25th 2024

Trajectory of Symptom Severity Aids Follow-Up in Head and Neck Cancer Treatment
Trajectory of Symptom Severity Aids Follow-Up in Head and Neck Cancer Treatment

April 27th 2024

Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC
Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC

April 22nd 2024

Video Interviews
Podcasts
Latest CME Events & Activities

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.